Jounce Therapeutics JNCE Stock
Jounce Therapeutics Price Chart
Jounce Therapeutics JNCE Financial and Trading Overview
| Jounce Therapeutics stock price | 1.88 USD |
| Previous Close | 1.88 USD |
| Open | 1.92 USD |
| Bid | 1.89 USD x 41800 |
| Ask | 1.93 USD x 40700 |
| Day's Range | 1.88 - 1.93 USD |
| 52 Week Range | 0.58 - 5.37 USD |
| Volume | 11.6M USD |
| Avg. Volume | 3.47M USD |
| Market Cap | 101.59M USD |
| Beta (5Y Monthly) | 0.751211 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2 USD |
JNCE Valuation Measures
| Enterprise Value | -81498280 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.8252428 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.2388581 |
| Price/Book (mrq) | 0.5307736 |
| Enterprise Value/Revenue | -0.994 |
| Enterprise Value/EBITDA | 1.625 |
Trading Information
Jounce Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.751211 |
| 52-Week Change | -59.56% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.37 USD |
| 52 Week Low | 0.58 USD |
| 50-Day Moving Average | 1.64 USD |
| 200-Day Moving Average | 1.93 USD |
JNCE Share Statistics
| Avg. Volume (3 month) | 3.47M USD |
| Avg. Daily Volume (10-Days) | 1.96M USD |
| Shares Outstanding | 52.64M |
| Float | 29.81M |
| Short Ratio | 0.48 |
| % Held by Insiders | 15.98% |
| % Held by Institutions | 85.33% |
| Shares Short | 2.02M |
| Short % of Float | 4.36% |
| Short % of Shares Outstanding | 3.85% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -62.095% |
| Operating Margin (ttm) | -63.71% |
| Gross Margin | 33.16% |
| EBITDA Margin | -61.16% |
Management Effectiveness
| Return on Assets (ttm) | -14.036% |
| Return on Equity (ttm) | -25.027% |
Income Statement
| Revenue (ttm) | 82M USD |
| Revenue Per Share (ttm) | 1.59 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 27.2M USD |
| EBITDA | -50155000 USD |
| Net Income Avi to Common (ttm) | -50919000 USD |
| Diluted EPS (ttm) | -0.96 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 189.54M USD |
| Total Cash Per Share (mrq) | 3.64 USD |
| Total Debt (mrq) | 10.02M USD |
| Total Debt/Equity (mrq) | 5.47 USD |
| Current Ratio (mrq) | 8.369 |
| Book Value Per Share (mrq) | 3.542 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -28877000 USD |
| Levered Free Cash Flow (ttm) | -12423250 USD |
Profile of Jounce Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 780 Memorial Drive |
| ZIP | 02139 |
| Phone | 857 259 3840 |
| Website | https://jouncetx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 141 |
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy. In addition, its preclinical products are JTX-1484, a monoclonal antibody designed to reduce myeloid-mediated immune suppression; and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression and activate T and NK cells. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Q&A For Jounce Therapeutics Stock
What is a current JNCE stock price?
Jounce Therapeutics JNCE stock price today per share is 1.88 USD.
How to purchase Jounce Therapeutics stock?
You can buy JNCE shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Jounce Therapeutics?
The stock symbol or ticker of Jounce Therapeutics is JNCE.
Which industry does the Jounce Therapeutics company belong to?
The Jounce Therapeutics industry is Biotechnology.
How many shares does Jounce Therapeutics have in circulation?
The max supply of Jounce Therapeutics shares is 54.04M.
What is Jounce Therapeutics Price to Earnings Ratio (PE Ratio)?
Jounce Therapeutics PE Ratio is 0.00000000 now.
What was Jounce Therapeutics earnings per share over the trailing 12 months (TTM)?
Jounce Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Jounce Therapeutics company belong to?
The Jounce Therapeutics sector is Healthcare.
Jounce Therapeutics JNCE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}